event guide -...

EVENT GUIDE

Delivering Solutions for Nucleic Acid TherapeuticsTwo Locations. One Approach. One Agilent.

Partner with Agilent's Nucleic Acid Solutions Division and benefit from industry leading experience to efficiently advance your lead oligo candidates from clinic to market with a common goal of patient health and safety.

Building on our success

– State of the art equipment trains

– World class analytical services

– Consistent approach to process development and scale-up

www.agilent.com/chem/[email protected]

This information is subject to change without notice.

© Agilent Technologies, Inc. 2019 Published in the USA, January, 2019 5991-9355EN

Boulder, Colorado

Frederick, Colorado

Agilent Technologies completing a new facility in ColoradoAgilent Technologies has acquired a 20 acre plot in Frederick, Colorado. Construction of the new pharmaceutical facility will be completed in 2018 and cGMP operations will commence in 2019.

The expansion will enable the company to more than double its commercial manufacturing capacity for nucleic acid based therapeutics.

Continuing to break new ground in nucleic acid therapeutics manufacturing When your next clinical trial or patient's well being depends on API availability, security of supply is a top priority.

Put your trust in Agilent to meet your clinical and commercial needs.

Agilent's Boulder, Colorado manufacturing site is a U.S. Food & Drug Administration (FDA) inspected facility and Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) accredited foreign manufacturer for non-sterile drugs.

AsiaTides Project Team...............................................................................................................................................................................ProductionMichael Keenan

MarketingAllison MacDonald

SponsorshipPerri Lucatello

OperationsRoshni Shah

Delegate SalesGeorge BriggsOctavia ConnellyMehmet Ismail

AsiaTides Event Guide -3

WELCOM

E

Welcome to AsiaTIDES:

We are very excited to welcome you to Tokyo and to present a fantastic line-up of international experts who will share their strategies, technologies and data to accelerate oligonucleotide, peptide, mRNA and other therapeutics from to the clinic to CMC manufacturing and beyond.We hope you take advantage of all the networking and learning opportunities at the event including 50+ speakers, 15+ posters and an exhibit hall of technology and service providers to help you with your R&D.Be sure to login and use the conference networking app which will allow you to view the attendee list and schedule meetings with other participants. And don’t hesitate to contact us at the conference registration desk if we can help you in any way during the conference.

Sincerely,

Must attend sessions:• Accelerating Oligonucleotides to IND and Beyond- Tuesday am• Accelerating Peptides to IND: Moving to the Clinic, CMC and Beyond– Tuesday am• Plenary Keynote Session – Tuesday pm• mRNA Therapeutics – Wednesday am• Regulatory Strategies for Peptides and Oligonucleotides – Thursday am

TIDES: Oligonucleotide &Peptide Therapeutics Digital Week

LEARN MORE AT WWW.TIDESDIGITALWEEK.COM

September 16-19, 2019

Have you heard about TIDES Digital Week? Join us for a 4-day series of live educational webcasts and downloadable resources uncovering insights to accelerate oligonucleotide and peptide products from early discovery to commercialization

SESSIONS ON HOT TOPICS• Oligonucleotide Chemistry Manufacturing and Controls

• Peptide Chemistry Manufacturing and Controls

• Peptide Discovery, Preclinical and Clinical

• Oligonucleotide Discovery, Preclinical and Clinical

4-DAY WEBCAST SERIES

AsiatidesDWFP.indd 1 2/5/19 9:58 AM

InformationIf you have any queries throughout the event please visit the registration desk and speak to a member of KNect365 staff.

Personal BelongingsPlease keep your valuables and workign material with you at all times. We would advise you to keep your notes with you as these cannot be replaced if lost. We regret that neither KNect365 Life Sciences nor the venue can be held responsible for any loss or damage to your property.

Security and Badge ScanningWe may ask to scan your badge for security and monitoring purposes.Please note that when scanned by an exhibitor, the bar code on your badge allows the exhibitor to collect your contact details which they will use to contact you for the purposes of event follow-up and to send you marketing information about their products and services.If you do not wish to share your contact information with the exhibitor for these purposes, please do not give the exhibitor permission to scan your badge.

HIGHLIGHTS & INFORMATION


NETWORKING DRINKS RECEPTION

All registered attendees include access to the attendee networking app that allows you to:• View the full attendee list of the co-located AsiaTIDES, Cell Therapy Manufacturing Asia, BPI Asia and Antibody Engineering Asia meetings• Send meeting requests• Build your individual and company profile• Post announcements

• Access speaker presentationsAll attendees were emailed log in details before the event, but come visit the registration desk if you need your log in details.

https://connect.jujama.com/AsiaTIDES-Cell-Therapy-BPI-Antibody-Engineering

Attendee Networking App

WIFI

AsiaTides 2020For sponsorship opportunities at AsiaTides 2020, please visit the Sales Office at registration

Network: Hilton HonorsPassword: knect365

Enjoy networking with your fellow attendees at our drinks reception

Date: Wednesday 27th (Day 2)Location: Exhibition Hall

Time: 5.30pm - 7pm

Sponsored by:

STAY ENGAGED YEAR ROUND WITH TIDES EVENT SERIES

TIDES May 20-23, 2019San Diego, CAwww.TIDESEvent.com

TIDES EuropeNovember 12-15, 2019Amsterdam, Netherlandswww.TIDESEuropeEvent.com

AsiaTIDESFebruary 24-26, 2020Kyoto, Japanwww.AsiaTIDESEvent.com

www.TIDESEventSeries.com

TidesSeriesAd.indd 1 2/1/19 12:59 PM

The fire alarm sound in this building is a siren

If you discover a fire raise the alarm by breaking the glass at the fire point

Do not stop to collect your belongings or use lifts

Do not obstruct any exits or gangways

There is a no smoking policy at this event

Please make yourself aware of the emergency exits in your immediate area

The assembly point for this event is located either in the hotel car park

Should you require special assistance please tell a member of KNect365 staff

Please be responsible when plugging laptop and mobile chargers into sockets

Data ProtectionDue to increased data protection legislation, we are now unable to distribute attendees’ contact details. Should you wish to contact anyone please either log into the Networking App (details on page 1 of this Guide) or speak to a member of staff at the KNect365 desk and we will be happy to pass your details to the person you would like to contact.

Environmental PolicyKNect365 is committed to a role of environmental and sustainable leadership in every aspect of our business and recognises the responsibilities we have to our employees, our customers, our suppliers, the communities we work within and the environment as a whole. Our contribution to a sustainable and environmentally harmonious society is based upon best practice and covers:Environment: We use recycled materials for office and event documentation and recycle all event plastic badge holders and lanyards.Community: To encourage sustainable development in the wider business we endeavour to utilise environmentally accredited venues and support regional agricultural practice by insisting on using locally grown produce for catering at all our large events.Relationships: Informa has developed an alliance with the Carbon Neutral Company and as a further example of our customer centricity, we strive to locate our events central to where we feel the majority of delegates originate.

Disclaimer

Although the content of conference materials is believed to be accurate, neither

Informa nor its presenters make any representations or warranties regarding such

content or materials.

Please note that:- (a) anybody using or relying upon information or opinions set

out in the conference materials, does so at their own risk; (b) Informa and its pre-

senters strongly advise that independent professional judgment be exercised and/

or independent professional advice should be sought before using or relying upon

such information or opinions; and (c) some of the views and opinions expressed by

presenters may be their own and may not necessarily represent the views or

opinions of the companies or organisations by whom they are engaged or

employed.

Liability for Lost or Stolen ItemsKNect365 will not accept any liability for loss, theft, damage or delay resulting from the loss or theft of any item of property belonging to participants or authors or third party, and the authors and partici-pants and third party agree that it is their responsibility to have in place adequate insurance to cover all such eventualities.Notwithstanding the provisions of the above paragraph, in the event that such items are taken into the custody of Informa or its representatives, Informa will exercise reasonable care but its liability for any such item for loss, theft, damage or delay whilst in the care of KNect365 or its representatives will not exceed the value of any item or £1,000, whichever is the lower.KNect365 may make a reasonable charge for the return of lost or unclaimed property to the participant or author or third party depending upon:-the type of article; and-the period during which KNect365 has held the article before it is claimed.

HEALTH & SAFETY


The emergency exit is located in Parking A

For information please contact us at [email protected]

PNA and DNA Structures The backbone of the PNA molecule is madefrom repeating N-(2-aminomethyl) glycine units linked by amide bonds. The purine (A, G) and pyrimidine (C, T) bases are attached to the backbone by methylene carbonyl linkages. Unlike DNA or other DNA analogs, PNAs do not contain any pentose sugar moieties or phosphate groups. By convention, PNAs are depicted like peptides, with the N-terminus at the first (left) position and the C-terminus at the right.

Peptide Nucleic Acids are analogs of DNA in which the phosphate backbone is replaced with a peptide like backbone. Due to their unique structure, PNA molecules have possible applications as antisense therapeutics, diagnostic markers, or molecular biology products.

PNA oligomers have several very desirable properties. • Bind specifically and tightly to complementary DNA and RNA strands. • Are neutral molecules with good solubility.

• Do not have chiral centers. • Are resistant to nucleases and proteases. • Can be synthesized using existing Fmoc and t-Boc solid phase synthesis techniques. PNA Monomers

O ONH

OO

O

OH

The Fmoc, Bhoc-protected A,C,G,T monomers; Fmoc-AEEA-OH; t-Boc (z) protected PNA Monomers.

PEPTIDE NUCLEIC ACID MONOMERS +H3N

N

B

O

NHO

N

B

O

NHO

N

B

O

NH2O

n

OHO

O OP O-O O

O OP O-O O

OH

B

B

Bn

PNA DNA

NN

NO O

OHNH

OO

OO NH

O

N

N N

NNH

O

O

N

O OOHN

HO

O

HNN

NO O

OHNH

OO

O

OCH3

HNN N

N

NO O

OHNH

OO

OO

O

HN

Description Quantity Catalog No 1060-61 Gram to Bulk QuantitiesFmoc‐A‐(Bhoc)‐aeg‐OH 3060-61 Gram to Bulk Quantities Fmoc‐C‐(Bhoc)‐aeg‐OH 7060-61 Gram to Bulk Quantities Fmoc‐G(Bhoc)‐aeg‐OH 0260-61 Gram to Bulk Quantities Fmoc‐T‐aeg‐OH

t‐Boc‐A(z)‐aeg‐OH

16‐2007 t‐Boc‐G(z)‐aeg‐OH 16‐2020 t‐Boc‐T‐OH

t‐Boc‐C(z)‐aeg‐OH Gram to Bulk QuantitiesGram to Bulk QuantitiesGram to Bulk QuantitiesGram to Bulk Quantities

16‐2001 16‐2003

N

N OO

NHO

O

NOH

ONH

O

O

N

N N

N

O

NHOO

NOH

ONH

OO

HN

N N

N

ONH

OO

O

NOH

ONH

O

O

HN

N OO

O

NOH

O

NH

OO

10 Powers Street · Leominster, MA 01453 · USA · Phone: 978-466-7978 Fax: 978-466-8084 · www.polyorginc.com

ISO 9001:2015 Certified Company

ISO 9001:2015 Certi ed Company

PolyOrgSulfa (POS) – A New Sulfur Transfer Reagent for the Synthesis of Oligonucleotide Phosphorothioates

We have introduced a novel reagent called POS (3-phenyl 1,2,4-dithiazoline-5-one) as an alternative sulfurizing reagent.

Anion Exchange HPLC of 31 mer (2 μm) synthesized on CPG using POS. Oligo has 26% A; 34% G; 21% T and 19% C.

Anion Exchange HPLC of 25 mer (200 μm) DNA phosphorothioate, synthesized on CPG using POS. Oligo has 30% A; 40% G; 26% T and 4% C.

S S

NO

dithi li 5 )

Please contact us for more information and

a free sample to evaluate POS

*U.S. Patent #: 6,500,944

• Soluble and stable in anhydrous acetonitrile.• 25-mer of DNA phosphorothioate gives less than 1% P=O using 60 seconds of sulfurizing time and 6 equivalents of the reagent.• POS does not need co-solvent and aging• Odorless crystalline powder with formula weight 195.27.• 0.15M solution of POS in anhydrous acetonitrile is recommended.• Cat. #: 16-1517

10 Powers Street • Leominster, MA 01453 • USA Phone: 978-466-7978 • Fax: 978-466-8084 • www.polyorginc.com

Discoidal lipid nanoparticle-assited transcutaneous delivery of a STAT3-inhibiting peptide ameliorates psoriasis-like skin inflammationHyeongseop Keum, Graduate Student, KAIST

Sequential treatment of cancer nanovaccine combined with immune checkpoint blockade can effectively inhibit tumor relapseYujin Kim, Graduate Student, KAIST

Effects of eluton conditions in the purification of oligonucleotides by agarose- based anion exchange chromatographyJan Berglof, VP Technical Sales, Bio-Works Sweden AB

Project for Drug Discovery and Development by AMEDRyutaro Hirasawa, Deputy Director, Japan Agency for Medical Research and Development

Fabrication of gold nanoclusters that can be fabricated without control processes that can be efficiently functionalized with oligonucleotidesJeong Hun Kim, Chemical Engineer, Sungkyunkwan University

Sensitivity Control of Nucleic Acid Biomarker Detection Based on the Geometric Appearances of the Gold NanomaterialSo Yeon Ahn, Masters Student, Sungkyunkwan University

Poster 1

Poster 6

Poster 2

Poster 3 Poster 4

Poster 5

POST

ERS

Research and development of core technologies for gene and cell therapyMichiko Takakura, Deputy Manager, AMED (Japan Agency for Medical Research and Development)

Large Scale liquid phase synthesis of CarbetocinMohammed Mohosin Layek, Senior Research Scientist, Neuland Labs

Poster 8Poster 7

Condition Study of Synthetic Peptide Separation by High-performance Cation Exchange ChromatographyToshito Kamichika, Tosoh Bioscience

Separation of oligonucleotides using synthetic adsorbentJun Takehara, Manager, Mitsubishi Chemical Co.

Poster 10Poster 9

Highly efficient production system of target RNA by microorganismShuhei Hashiro, Research Scientist, AJINOMOTO CO., INC

Efficacy of eye-drop type POLIGOTM for the prevention of retinal neovascularization in a rat modelHye Joo Kim, CEO, SEASUN THERAPEUTICS. Inc

Poster 12Poster 11

Key Critical Quality Attributes for the cGMP Production of Therapeutic Messenger RNAJessica Madigan, Sr. Business Development Manager, GMP, TriLink BioTechnologies

Poster 13

AGENDA DAY 1 - TUESDAY, 26 FEBRUARY

8.30 RegistrationWORKSHOP 1:

Accelerating Oligonucleotides to IND and Beyond

Room: Ami

WORKSHOP 2:

An Introduction to Peptide Therapeutic

Development: Strategies for Moving to the Clinic, CMC

and Beyond

Room: Evo

9:00 Workshops

Bruce Morimoto, PhD- Vice President, Scientific Affairs, Alkahest

Christopher Rhodes, PhD- President and CEO, Drug Delivery Experts

9:15 Challenges in Synthesis of the Peptide API

Robert Hagopian- Director Business Development, PolyPeptide

Group

10:00 Analytical Methods, Pre-formulation, and Formulation for

Early Phase

Christopher Rhodes, PhD- President and CEO, Drug Delivery Experts

11:15 IND-enabling, Nonclinical Safety Studies for Peptides:

Pharmacokinetics, Bioanalytsis and Toxicology


12:00 Similarities and Differences in the Product Development

between a Peptide Drug and a Peptide Biologic in the US

Duu-Gong Wu, PhD- Senior Director, Regulatory Consulting, PPD

12:45 Lunch for workshop attendees only

1:55 Chairperson's Remarks


2:00 RNAi Therapeutics Delivered: Improving Pharmacological Properties of siRNAs

Muthiah (Mano) Manoharan, PhD- Senior Vice President of Drug Discovery, Alnylam Pharmaceuticas, Inc.

2:30 The Discovery of Semaglutide- A Journey from Ala Scan to Structural Design of GLP-1 Analogues

Jesper Lau, PhD- Vice President, Protein and Peptide Chemistry, Novo Nordisk A/S

3:00 New Strategies and Technologies in Oligonucleotide Therapeutic Development*

Thazha P. Prakash, Ph.D.- Director, Medicinal Chemistry, Ionis Pharmaceuticals

3:30 Networking Refreshment Break

4:00 Recent Progress in Ribosomal in-vitro Expression of Pseudo-natural Peptides

Hiroaki Suga, Ph.D.- Professor of Chemistry, School of Science, University of Tokyo, Japan

4:30 The Oligo Therapeutics Market Landscape - A 17 Year Retrospective on Market Trends, Deals, Investments and Key Clinical

Developments and a Look to the Future*

Alun Garner- Business Development Manager, Nucleic Acid Solutions Division, Agilent Technologies, Inc.

5.45 Networking Dinner Please note you must be already registered for the Dinner

Meet at the hotel lobby at 5.45, coaches will depart at 6pm. AsiaTides Event Guide -11

PLENARY KEYNOTE SESSIONS Room: Soara Ӏ

9:00 Workshop Co-Moderators' Opening Remarks

Marc Lemaître, PhD- Chief Operating Officer/ Principal Sirnaomics,

Inc./ ML Consult

Thomas Rupp- Owner & Principal, Thomas Rupp Consulting,

Germany

10:45 Networking Refreshment Break

9:15 The Chemistry behind Approved Oligonucleotide Therapeutics

Muthiah (Mano) Manoharan, PhD- Senior Vice President of Drug

Discovery, Alnylam Pharmaceuticals, Inc.

09:45 Oligo Synthesis Scale-up and Process Related Issues and

Troubleshooting

Thomas Rupp- Owner & Principal, Thomas Rupp Consulting,

Germany

11:15 CMC Oligos - Real World Case-studies

Marc Lemaître, PhD- Chief Operating Officer/ Principal Sirnaomics,

Inc./ ML Consult

12:00 CureVac's RNA Technology as Basis for Product

Development

Florian von der Mülbe, Ph.D., Chief Production Officer, Curevac,

Germany

Download speaker presentations from https://lifesciences.knect365.com/

asia-tides/presentations

*Presentations marked with asterick will be unavailable to download

after the event due to the speakers’ company poilcies

WEDNESDAY, 27 FEBRUARYOPENING PLENARY:

Room: Soara Ӏ8:00 Registration and Coffee

8:55 Chairperson's RemarksJames Thompson, PhD- Head of CMC Project Management, Moderna Therapeutics, Inc.

9:00 An Introduction to mRNA TherapeuticsJames Thompson, PhD- Head of CMC Project Management, Moderna Therapeutics, Inc.

9:30 Novel mRNA Immunotherapies*Robert Jabulowsky, PhD- Deputy Head of Project Management, BioNTech AG

10:00 Effective Delivery of Therapeutic Proteins by mRNA*Nigel Horscroft, D.Phil- Vice President Development RNArt, CureVac AG

10:30 Networking Refreshment Break with Poster and Exhibit Viewing

OLIGONUCLEOTIDE TRACK:OPTIMIZING PROPERTIES OF OLIGONUCLEOTIDES

Room: Soara Ӏ

PEPTIDE TRACK: PEPTIDE DISCOVERY AND PEPTIDE DRUG TARGETS

Room: Soara ӀӀӀ

11:45 Plants as Biofactories for Producing Peptide-based PharmaceuticalsDavid Craik, PhD- Professor of Biomolecular Structure, Institutre for Molecular Bioscience, University of Queensland

11:45 The Role of Base Modifications in Folding, Binding and Pharmacology of DNA- based AdtamersNebojsa Janjic, PhD- Chief Science Officer, SomoLogic, Inc.

12:15 Next Generation Locked Nucleic Acids*Konrad Bleicher, PhD- Expert Scientist, F.Hoffman-La Roche Ltd.

12:45 Networking Luncheon & Poster Viewing in Exhibit Hall

12:15 Genetically Encoded Selection of Novel Cyclic and Bicyclic ArchitecturesRatmir Derda, PhD- Associate Professor, Department of Chemistry, University of Alberta

11:15 Inhibition and Degradation of Drug Targets Using bioPROTAC mRNAs- A Novel Approach with Broad Therapeutic Potential*Jeff Chang, PhD- Associate Scientist and Post Doc Fellow, MSD International GmbH (Singapore)


Robert Gronke, Ph.D., Senior Principal Scientist, Technical Development, Biogen, USA


Yoshio Hayashi, PhD- Professor, Department of Medicinal Chemistry, Tokyo University of Pharmacy and Life Science

11:15 From Stereopurity to Precision Medicine: Optimizing the Properties of Antisense*Chandra Vargeese, PhD- SVP, Head of Drug Discovery, WAVE Life Sciences

11:10 Chairperson's RemarksThazha P. Prakash, Ph.D., Executive Research Fellow, Ionis Pharmaceuticals, USA

11:10 Chairperson's RemarksRatmir Derda, Ph.D., Associate Professor, Department of Chemistry, University of Alberta, Canada

2:00 An Update on the DCR- PHXC ProgramJennifer Lockridge, PhD- Senior Vice President, Program Development, Dicerna Pharmaceuticals

2:00 Intracellular Screening for Selective Antagonists of an Oncogenic Transcriptional RegulatorJody Mason, PhD- Senior Lectuer in Biochemistry, University of Bath

2:30 Massively Parallel Synthesis and Lead Optimization of PeptidomimetricsJigar Patel- Director, Roche Madison

2:30 Optimizing Delivery of mRNA TherapeuticsPeter Lutwyche, PhD- Chief Technology Officer, Genevant Sciences Corporation

Agen

da D

ay Tw

o- W

edne

sday

, 27

Febr

uary

Agenda Day Two- W

ednesday, 27 FebruaryDownload speaker presentations from

https://lifesciences.knect365.com/asia-tides/presentations


after the event due to the speakers’ company poilcies

OLIGONUCLEOTIDE TRACK:OLIGONUCLEOTIDE CMC STRATEGIES

Room: Soara Ӏ

PEPTIDE TRACK: OPTIMIZING PEPTIDE PROPERTIES

Room: Soara ӀӀӀ

3:00 Process Development and GMP Manufacturing of DNA AdjuvantsSatoshi Inoue, PhD- Scientist, Research & Development Division, GeneDesign, Inc.

3:30 Networking Refreshment Break with Exhibit and Poster Viewing

3:00 A New Scenario for Disulfide Peptide Synthesis Based on Npys ChemistryYoshio Hayashi, PhD- Professor, Department of Medicinal Chemistry, Tokyo University of Pharmacy and Life Science

4:00 Antisense Oligonucleotide Purification Process: Successes and Challenges During Scale-UpRobert Gronke, PhD- Senior Principal Scientist, Technical Development, Biogen, Inc

4:00 Peptide Drug Discovery Case Study: Appropriate Screening for ADME Properties and Pseudo Allergic Reactions at An Early Stade is Key to Success*Raffaele Ingenito, PhD- Senior Scientist, IRBM Science Park

4:30 NittoPhase® HL, High Loading Polymeric Solid Support for Efficient and Cost-Effective Oligonucleotide SynthesisMohammad Ahmadian, Ph.D.- Senior Director, Kinovate Life Sciences, A Nitto Company

4:30 Beyond Antibodies: Targeting VEGF-A and PD-1 with Synthetic D-proteinsDana Ault-Riche, Ph.D.- CEO, Reflexion Pharmaceuticals

5:00 Utilising NMR for Oligonucleotide CharacterisationThomas Brown- Senior Scientist- Oligonucleotides, Intertek Pharmaceutical Services

5:00 Of Peptides and PANDAS: Innovative Preclinical Assessment Tools for Safety and Efficacy of Protein and Peptide TherapeuticsAnnie De Groot, MD- Founder, CEO and CSO, Epivax, Inc.

5:30 Networking Cocktail Reception in the Exhibit and Poster Hall

Sponsored by


THURSDAY 28, FEBRUARYOPENING PLENARY:

Room: Soara Ӏ8:00 Registration and Coffee

8:40 Chairperson's RemarksDuu-Gong Wu, PhD- Senior Director, Regulatory Consulting, PPD

8:45 Regulatory and Clinical Development Strategy for Peptides in the Era of ICH; Oligonucleotide Products - Comparing the Regulatory Environment in US and ChinaDan Zhang, PhD- Co-Founder & CEO, Fountain Medical Development

9:15 US Regulatory Update: Peptide and Device Combination Products and the Lessons Learned from the Approval of Oligonucleotide Product, Macugen®Duu-Gong Wu, PhD- Senior Director, Regulatory Consulting, PPD

9:45 Understanding FDA's Draft Guidance for a Generic product of a Highly Purified Synthetic Peptide that References an Approved Application for a Recombinant Peptide Product*David Lin, PhD, MBA- Senior Consultant, Biologics Consulting Group, Inc.

10:15 Networking Refreshment Break with Poster and Exhibit Viewing

OLIGONUCLEOTIDE TRACK:DELIVERY STRATEGIES

Room: Soara Ӏ

PEPTIDE TRACK: PEPTIDE CMC STRATEGIES

Room: Soara ӀӀӀ

11:00 Introducing Green and Sustainable Solvents in Liquid Phase Peptide Manufacturing Processes

El Djouhar Rekaï, PhD- Head of Development & Manufacturing

Process, PolyPeptide Group

12:00 siRNA Delivery is Still the Key to Therapeutics SuccessDavid M. Evans, PhD- Co-Founder and CSO, Siraomics Inc., USA

1:45 NJA-730, The First Therapeutic Compound from NapaJen's Platform Delivery Technology for aGvHD (acute Graft versus Host Disease) Is in Clinical StageKenji Arima, PhD- Chief Development Officer, NapaJan Pharma Co. Ltd.

12:30 Networking Luncheon & Poster Viewing in Exhibit Hall

11:30 Peptide Quality Attributes and USP StandardsRanjan Chakrabarti, PhD- Vice President, Biologics & Biotechnology, United States Pharmacopeia

12:00 Cost Efficient Peptide Purification via ZEOsphere DRP Mixed-Mode ChromatographyJurgen Machielse- Business Development Director, Zeochem AG


David Horn Solomon, M.D- CEO, Silence Therapeutics, United Kingdom

1:40 Chairperson's RemarksYoon Jeong Park, Ph.D., Professor, Seoul National University and Chief Technology Officer, NIBEC, South Korea

11:30 Emerging RNA Therapeutics: Delivery Approaches for mRNA, siRNA and BeyondShiro Akinaga, PhD- Director and CSO, AccuRna

10:55 Chairperson's RemarksDavid M. Evans, PhD- Co-Founder and CSO, Siraomics Inc., USA


El Djouhar Rekaï, PhD- Head of Development & Manufacturing

Process, PolyPeptide Group

1:45 Linear and Convergent Approaches to Peptide Synthesis - A Comparison from A Manufacturer's Point of View*Daniel Samson, PhD- Vice President, API SPPS, Bachem AG

11:00 MicroRNA-155 Inhibition by Cobomarsen Demonstrates Encouraging Activity in Hematological Malignancies*William Marshall, PhD- President and Chief Executive Officer, miRagen Therapeutics, Inc.

Agen

da D

ay Th

ree-

Thur

sday

, 28

Febr

uary

Download speaker presentations from https://lifesciences.knect365.com/

asia-tides/presentations


after the event due to the speakers’ company poilciesAgenda Day Three- Thursday, 28 February

2:15 Anti-FGF2 Aptamer RBM-007 in Phase I/IIa trials for Wet AMDYoshikazu Nakamua, PhD- President and CEO, Ribomic Inc

OLIGONUCLEOTIDE TRACK:OLIGONUCLEOTIDE CASE STUDIES

Room: Soara Ӏ

PEPTIDE TRACK: PEPTIDE DEVELOPMENT AND PEPTIDE DELIVERY

Room: Soara ӀӀӀ

2:15 ESCAPE-NA1 and FRONTIER: Two Complementary Phase 3 Trials to Demonstrate and Safety and Efficacy of NA-1 in Acute Ischemic StrokeDave Garman, PhD- Vice President, API SPPS, Bachem AG

3:45 TANGO- Targeted-Augmentation of Nuclear Gene Output - for the Treatment of Genetic DiseasesHuw Nash, PhD- Chief Operating Officer and Chief Business Officer, Stoke Therapeutics

3:15 Networking Refreshment Break with Exhibit and Poster Viewing

2:45 The Orally Available Clinical Stage All-D-enantiomeric peptide PRI-002 Reverses Cognition Deficits and Decelerates Neurodegeneration in Transgenic Alzheimer's Mouse ModelsDieter Willbold, PhD- Director, ICS-6 Structural Biochemistry, Forschungszentrum, Jülich, Germany

2:45 Therapeutic RNA Medicines: The Silence Therapeutics Experience in Haematology and Rare DiseaseDavid Horn Solomon, M.D- CEO, Silence Therapeutics, United Kingdom

4:15 A phase 1/2 study of ENA® antisense oligonucleotide, DS-5141b, with exon 45 skipping activity in patients with DMDOsamu Sato, PhD- Execuive Director, R&D Planning Department, Daiichi Sankyo Co., Ltd

4:45 Asymmetric siRNA Targeting Fibrotic and Ocular DisordersDong-Ki Lee, PhD- CEO, QliX Pharmaceuticals

3:45 Development of a Peptide Vaccine for the Induction of Epitope-specific Hideki Tomioka, PhD- Member of the Board, FunPep Co., Ltd

4:15 Osseotide, A Synthetic, Selective Osteogenic Peptide for the Treatment of OsteoporosisYoon Jeong Park, Ph.D., Professor, Seoul National University and Chief Technology Officer, NIBEC, South Korea

5:15 End of Conference


4:45 Close of Peptide Track

FLOO

RPLA

N

COMPANY STAND NUMBERAgilent Technologies 2Asahi Kasei Bioprocess America, Inc. 1 Bachem Americas, Inc. 20BCN Peptides 17BianoGMP 9ChemGenes 8Curachem Inc 12GeneDesign 5Guangzhou RiboBio 14Hongene Biotechnology 3 Intertek 11Kinovate Life Sciences 21

COMPANY STAND NUMBERMitsubishi Chemical Co 10Neuland Labs 19Nitto Denko Avecia 13PolyPeptide Group 18

The United States Pharmacopeial Convention 8A Tosoh Bioscience 6TriLink BioTechnologies 15

Zhejiang peptites Biotech Co. Ltd 16

KNECT365 REGISTRATION DESK

SPONSORS & EXHIBITORS

GOLD SPONSORS...............................................................................................................................

SILVER SPONSORS...............................................................................................................................

EXHIBITORS...............................................................................................................................

SESSION SPONSOR...............................................................................................................................


BAG SPONSOR

MEDIA PARTNERS...............................................................................................................................

NOTE

S

February 24-26, 2020The Westin Miyako KyotoKyoto, Japan

THE ONLY EVENT IN ASIA BRINGING TOGETHER SCIENCE, TECHNOLOGIES AND PARTNERS TO ACCELERATE OLIGONUCLEOTIDE AND PEPTIDE MOLECULES TO MARKET

Pre-register for AsiaTIDES 2020 with VIP code “ASIA19” to receive 10% offwww.AsiaTIDESevent.com

Thank you for making this year a success!Join us again next year!

Asiatides2020FP.indd 1 2/5/19 10:52 AM

event guide -...

Documents